{"id":22696,"date":"2023-01-18T16:27:00","date_gmt":"2023-01-18T08:27:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22696"},"modified":"2025-01-23T16:32:07","modified_gmt":"2025-01-23T08:32:07","slug":"structure-therapeutics-files-for-ipo-on-nasdaq-to-raise-119m","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22696","title":{"rendered":"Structure Therapeutics Files for IPO on NASDAQ to Raise $119M"},"content":{"rendered":"\n<p>Structure Therapeutics Inc. (Nasdaq: GPCR), a Sino-US firm formerly known as ShouTi Inc., has filed for an initial public offering (IPO) on the NASDAQ stock exchange. The company aims to raise USD 119 million gross through the issuance of American Depositary Shares (ADS), though the final figure may differ. Structure operates out of San Francisco and Shanghai, with ambitions to replace biologics and peptides with superior small molecule drugs, specifically targeting G-protein coupled receptors (GPCR) using its structure-based drug design platform and advanced computational technologies.<\/p>\n\n\n\n<p><strong>Pipeline and Lead Candidate<\/strong><br>The funds raised from the IPO will support the development of Structure&#8217;s pipeline. The lead candidate is a glucagon-like-peptide-1 receptor (GLP-1R)-targeted molecule for type 2 diabetes and obesity, currently completing a Phase Ib study and preparing for a Phase IIa proof-of-concept trial. The company also has a GLP-1R\/GIPR (gastric inhibitory polypeptide receptor) agonist in the discovery stage, an apelin receptor (APJR) agonist for cardiopulmonary indications in Phase I, and a differentiated lysophosphatidic acid 1 receptor (LPA1R) antagonist for idiopathic pulmonary fibrosis (IPF) at the IND-enabling stage.<\/p>\n\n\n\n<p><strong>Financing and Backers<\/strong><br>Structure Therapeutics has attracted USD 188 million in financing rounds, with backers including a string of Asia-based and Chinese investors such as Lilly Asia Ventures, Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital, and Wuxi AppTec. The IPO represents a significant step in the company&#8217;s growth strategy, positioning it to further develop its innovative pipeline of GPCR-targeted therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Structure Therapeutics Inc. (Nasdaq: GPCR), a Sino-US firm formerly known as ShouTi Inc., has filed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[39,72,3264],"class_list":["post-22696","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-diabetes","tag-ipo","tag-structure-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Structure Therapeutics Files for IPO on NASDAQ to Raise $119M - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Structure Therapeutics Inc. (Nasdaq: GPCR), a Sino-US firm formerly known as ShouTi Inc., has filed for an initial public offering (IPO) on the NASDAQ stock exchange. The company aims to raise USD 119 million gross through the issuance of American Depositary Shares (ADS), though the final figure may differ. Structure operates out of San Francisco and Shanghai, with ambitions to replace biologics and peptides with superior small molecule drugs, specifically targeting G-protein coupled receptors (GPCR) using its structure-based drug design platform and advanced computational technologies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22696\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Structure Therapeutics Files for IPO on NASDAQ to Raise $119M\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22696\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-18T08:27:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-23T08:32:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22696#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22696\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Structure Therapeutics Files for IPO on NASDAQ to Raise $119M\",\"datePublished\":\"2023-01-18T08:27:00+00:00\",\"dateModified\":\"2025-01-23T08:32:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22696\"},\"wordCount\":258,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Diabetes\",\"IPO\",\"Structure Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22696#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22696\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22696\",\"name\":\"Structure Therapeutics Files for IPO on NASDAQ to Raise $119M - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-01-18T08:27:00+00:00\",\"dateModified\":\"2025-01-23T08:32:07+00:00\",\"description\":\"Structure Therapeutics Inc. (Nasdaq: GPCR), a Sino-US firm formerly known as ShouTi Inc., has filed for an initial public offering (IPO) on the NASDAQ stock exchange. The company aims to raise USD 119 million gross through the issuance of American Depositary Shares (ADS), though the final figure may differ. Structure operates out of San Francisco and Shanghai, with ambitions to replace biologics and peptides with superior small molecule drugs, specifically targeting G-protein coupled receptors (GPCR) using its structure-based drug design platform and advanced computational technologies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22696#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22696\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22696#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Structure Therapeutics Files for IPO on NASDAQ to Raise $119M\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Structure Therapeutics Files for IPO on NASDAQ to Raise $119M - Insight, China&#039;s Pharmaceutical Industry","description":"Structure Therapeutics Inc. (Nasdaq: GPCR), a Sino-US firm formerly known as ShouTi Inc., has filed for an initial public offering (IPO) on the NASDAQ stock exchange. The company aims to raise USD 119 million gross through the issuance of American Depositary Shares (ADS), though the final figure may differ. Structure operates out of San Francisco and Shanghai, with ambitions to replace biologics and peptides with superior small molecule drugs, specifically targeting G-protein coupled receptors (GPCR) using its structure-based drug design platform and advanced computational technologies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22696","og_locale":"en_US","og_type":"article","og_title":"Structure Therapeutics Files for IPO on NASDAQ to Raise $119M","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22696","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-01-18T08:27:00+00:00","article_modified_time":"2025-01-23T08:32:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22696#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22696"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Structure Therapeutics Files for IPO on NASDAQ to Raise $119M","datePublished":"2023-01-18T08:27:00+00:00","dateModified":"2025-01-23T08:32:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22696"},"wordCount":258,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Diabetes","IPO","Structure Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22696#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22696","url":"https:\/\/flcube.com\/?p=22696","name":"Structure Therapeutics Files for IPO on NASDAQ to Raise $119M - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-01-18T08:27:00+00:00","dateModified":"2025-01-23T08:32:07+00:00","description":"Structure Therapeutics Inc. (Nasdaq: GPCR), a Sino-US firm formerly known as ShouTi Inc., has filed for an initial public offering (IPO) on the NASDAQ stock exchange. The company aims to raise USD 119 million gross through the issuance of American Depositary Shares (ADS), though the final figure may differ. Structure operates out of San Francisco and Shanghai, with ambitions to replace biologics and peptides with superior small molecule drugs, specifically targeting G-protein coupled receptors (GPCR) using its structure-based drug design platform and advanced computational technologies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22696#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22696"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22696#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Structure Therapeutics Files for IPO on NASDAQ to Raise $119M"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22696"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22696\/revisions"}],"predecessor-version":[{"id":22698,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22696\/revisions\/22698"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}